EUDA Health Holdings amended its warrant agreement with Streeterville Capital, lowering the exercise price and closing price threshold.
Quiver AI Summary
EUDA Health Holdings Limited, a Singapore-based non-invasive healthcare provider focused on Asia, announced an amendment to its warrant agreement with Streeterville Capital, LLC. The amendment reduces the exercise price of the warrant from $6.00 to $4.00 per share and lowers the minimum closing price required for a forced exercise from $7.50 to $6.00. The original warrant, which allows for the purchase of up to 2 million ordinary shares for $100,000, was issued following a securities purchase agreement in late 2025. EUDA aims to lead in non-invasive and preventive healthcare in the region, addressing the needs of a rapidly aging population.
Potential Positives
- EUDA Health Holdings Limited successfully amended its warrant agreement, reducing the exercise price from US$6.00 to US$4.00 per share, making it more attractive for investors.
- The amendment includes a reduction in the minimum closing price required to trigger a "Forced Exercise" from US$7.50 to US$6.00, potentially leading to increased liquidity for the company.
- This strategic move may strengthen investor confidence and encourage more participation from stakeholders in the fast-growing longevity sector in Asia.
- EUDA positions itself as a leader in non-invasive healthcare solutions, addressing the healthcare needs of a rapidly aging population in a region with over 1.8 billion people.
Potential Negatives
- Reduction of the exercise price of the warrant from US$6.00 to US$4.00 may signal financial weakness or a lack of investor confidence in the company's stock valuation.
- Lowering the minimum closing price for a "Forced Exercise" from US$7.50 to US$6.00 could indicate that the company anticipates continued struggles with its share price, facilitating an easier path for warrant holders to convert at a lower threshold.
FAQ
What is the recent Warrant Amendment by EUDA Health?
EUDA amended its warrant agreement with Streeterville Capital, lowering the exercise price and minimum closing price for forced exercises.
Who is Streeterville Capital, LLC?
Streeterville Capital is a limited liability company based in Utah that has a warrant agreement with EUDA Health.
What does the Warrant allow Streeterville Capital to do?
The Warrant allows Streeterville Capital to acquire up to 2,000,000 ordinary shares of EUDA at a specified price.
How long is the Cash Exercise Period for the Warrant?
The Cash Exercise Period for the Warrant lasts for ninety days from the issuance date unless extended.
What is EUDA Health's mission?
EUDA aims to transform healthcare by providing innovative, non-invasive health solutions for aging populations in Asia.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$EUDA Hedge Fund Activity
We have seen 3 institutional investors add shares of $EUDA stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HUDSON BAY CAPITAL MANAGEMENT LP removed 476,100 shares (-59.8%) from their portfolio in Q3 2025, for an estimated $826,033
- CITADEL ADVISORS LLC added 16,321 shares (+57.7%) to their portfolio in Q3 2025, for an estimated $28,316
- GEODE CAPITAL MANAGEMENT, LLC added 4,626 shares (+28.8%) to their portfolio in Q3 2025, for an estimated $8,026
- UBS GROUP AG removed 4,551 shares (-99.0%) from their portfolio in Q3 2025, for an estimated $7,895
- SBI SECURITIES CO., LTD. added 10 shares (+inf%) to their portfolio in Q3 2025, for an estimated $17
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SINGAPORE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has entered into an amendment (the “Warrant Amendment”) to its previously disclosed warrant agreement with Streeterville Capital, LLC (“Streeterville Capital”).
Background on the Original Warrant Transaction
As previously announced, on November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital, a Utah limited liability company, for the issuance of a warrant (the “Warrant”) exercisable into up to 2,000,000 newly issued ordinary shares of EUDA for an aggregate purchase price of US$100,000. The Warrant was issued on December 4, 2025. The offer and sale of the Warrant and the Warrant Shares were made pursuant to a prospectus supplement dated December 4, 2025, as part of a registration statement on Form F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024 and declared effective on November 4, 2024. The Warrant may be exercised for cash for ninety (90) days (unless extended by the parties) from the date of issuance (the “Cash Exercise Period”). At the end of two weeks after the Cash Exercise Period has expired, Streeterville Capital will automatically be deemed to have made a “cashless” exercise of the Warrant, and the Company will be required to issue to Streeterville Capital one (1) ordinary share for every ten (10) outstanding Warrant Shares for no additional consideration.
Summary of Amended Terms
On December 16, 2025, EUDA and Streeterville Capital entered into the Warrant Amendment to (i) reduce the exercise price of the Warrant from US$6.00 per share to US$4.00 per share and (ii) reduce the minimum closing price required to trigger a “Forced Exercise” (defined in the Warrant) from US$7.50 to US$6.00. All other terms of the warrant remain unchanged.
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.
Forward-Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Christensen Advisory
Christian Arnell
Phone: + 852 9040 0621
Email:
[email protected]